Author

Jill Libles Feldman

Observed name: Jill Feldman

Observed institution: American Cancer Society

ORCID: 0000-0002-2107-8240

Observed ORCID: 0000-0002-2107-8240

OpenAlex ID: A5121237408

Therapy for Stage IV Non–Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, 2026.3.1

2026 · Joshua E. Reuss, Nofisat Ismaila, et al. · Journal of Clinical Oncology · 2

Metastatic Trajectories in Non–Small Cell Lung Cancer Guide Local and Systemic Therapies

2026 · Jonas Willmann, Edward Christopher Dee, et al. · Journal of Clinical Oncology · 1

Beyond Diagnosis: Survivorship Research for People Living with Advanced and Metastatic Cancers

2026 · Michelle A. Mollica, Jill Feldman, et al. · Cancer Epidemiology Biomarkers & Prevention · 1

Confronting nihilism and stigma in lung cancer: The nurse practitioner's role in restoring hope and trust

2025 · Lisa Carter-Bawa, Timothy J. Williamson, et al. · Journal of the American Association of Nurse Practitioners · 1

Clinical trial? Oh, I'm not ready for that! A cross-sectional study evaluating barriers to clinical trial accrual in patients with lung cancer.

2026 · Isabel Ruth Preeshagul, Mark M. Awad, et al. · JCO Oncology Practice

Who, what, when: A national survey of survivorship care delivery at US cancer centers.

2026 · Ameish Govindarajan, Jill Libles Feldman, et al. · JCO Oncology Practice

Hope for a cure: Exploratory analysis of prognostic awareness of people living with advanced lung cancer.

2026 · Chelsea Ducille, Upal Kunal Basu Roy, et al. · JCO Oncology Practice

Lung Cancer Patient Advocacy Progress and New Challenges Since 2006

2026 · Jean-Louis Pujol, Upal Basu Roy, et al. · Journal of Thoracic Oncology

Examining the impact of community, knowledge, and shared support on the EGFR -mutated lung cancer care journey: Results from the first annual EGFR Resisters Patient and Caregiver Summit.

2026 · Bryan Carson Taylor, Jill Libles Feldman, et al. · Journal of Clinical Oncology

PP01.142: First Results from the COCOON Treatment Substudy in Managing Moderate to Severe Dermatologic Adverse Events in Participants with EGFR-mutated Advanced NSCLC Treated with First-line Amivantamab-Lazertinib

2026 · Alexander I. Spira, Maxwell B. Sauder, et al. · Journal of Thoracic Oncology

PP01.20: The Patient Voice on Required Research Biopsies: Results of a Survey Study Exploring the Perspective of Patients with Lung Cancer

2026 · Faith Abodunrin, Miranda Kaye, et al. · Journal of Thoracic Oncology

Works count: 11

Citation count: 5

H-index: 1

I10-index: